FrancophonIA/ELRC3.0 huggingface dataset:
English: - If you are being treated for DFSP:
Slovenian: Če se zdravite zaradi DFSP:
English: * These types of reactions have been reported mainly from post-marketing experience with imatinib.
Slovenian: * O teh vrstah neželenih učinkov so poročali večinoma v okviru izkušenj v obdobju trženja zdravila z zdravilom Imatinib.
English: ANC ≥ 1 x 10
Slovenian: dokler ni ANC ≥ 1 x 10
English: - If you are being treated for MDS/MPD:
Slovenian: Če se zdravite zaradi MDS/MPD:
English: Cerebral oedema*
Slovenian: možganski edem*
English: The degree of cytogenetic response and molecular response had a clear effect on long-term outcomes in patients on imatinib.
Slovenian: Stopnja citogenetičnega in molekularnega odziva ima nedvomen učinek na dolgoročni izid pri bolnikih, zdravljenih z imatinibom.
English: Merckle GmbH Graf-Arco-Str. 3, 89079 Ulm Germany
Slovenian: Merckle GmbH Graf-Arco-Str. 3, 89079 Ulm
English: The primary efficacy variable of the study was the rate of major cytogenetic response (complete plus partial response, 0 to 35% Ph+ metaphases in the bone marrow).
Slovenian: Primarna učinkovitostna spremenljivka študije je bila stopnja pomembnega citogenetičnega odziva (popolni plus delni odziv, 0 do 35 % Ph+ metafaz v kostnem mozgu).
English: Imatinib Teva inhibits the growth of these cells in a certain subtype of these diseases.
Slovenian: Zdravilo Imatinib Teva zavira rast teh celic pri določenih podskupinah teh bolezni.
English: This clinical effect was associated with a higher reduction in bcr-abl transcripts in the imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02).
Slovenian: Ta klinični učinek je bil povezan z večjim zmanjšanjem količine transkriptov bcr abl pri bolnikih, zdravljenih z imatinibom, kot pri skupini, zdravljeni s kemoterapijo po 2 tednih zdravljenja (p=0,02).
English: PLIVA Croatia Ltd. Prilaz baruna Filipovica 25 10000 Zagreb Croatia
Slovenian: Prilaz baruna Filipovica 25 10000 Zagreb Hrvaška
English: 21 patients were treated with imatinib 400 mg daily, while the other 3 patients received lower doses.
Slovenian: 21 bolnikov je prejemalo imatinib v odmerku 400 mg na dan, drugi 3 bolniki pa so prejemali manjše odmerke.
English: ANC = absolute neutrophil count a occurring at least after one month of treatment
Slovenian: ANC = absolutno število nevtrofilcev (absolute neutrophil count) a do katere pride po najmanj 1 mesecu zdravljenja
English: Experience with imatinib in this indication is very limited and is based on haematological and cytogenetic response rates.
Slovenian: Za to indikacijo je izkušenj z imatinibom zelo malo in temeljijo na hematološki in citogenetični odzivnosti.
English: The length of the capsule is from 23.0 mm to 23.6 mm and the width is 8.53 mm.
Slovenian: Dolžina kapsule znaša od 23,0 mm do 23,6 mm in je široka 8,53 mm.
English: • Sudden swelling and redness of the skin (signs of a skin infection called cellulitis).
Slovenian: • nenadna oteklina in pordelost kože (znaki kožne okužbe z imenom flegmona (celulitis)),
English: In contrast, there were 165 (29.8%) events in the IFN+Ara-C arm, of which 130 occurred during first-line treatment with IFN+Ara-C.
Slovenian: Za razliko od tega je bilo v kraku z IFN+AraC 165 (29,8 %) dogodkov, od tega se jih je 130 zgodilo v času zdravljenja z IFN+Ara-C kot zdravilom prvega izbora.
English: However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the
Slovenian: vendar pa je pojavljanje citopenij tudi nedvomno odvisno od stadija bolezni.
English: The median duration of second-line treatment with imatinib was 64 months.
Slovenian: Mediano trajanje zdravljenja z imatinibom kot zdravilom drugega izbora je bilo 64 mesecev.
English: Neoplasm benign, malignant and unspecified (including cysts and polyps) Rare
Slovenian: Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
English: If this applies to you, tell your doctor without taking Imatinib Teva.
Slovenian: Če to velja za vas, povejte zdravniku in ne jemljite zdravila Imatinib Teva.
English: (0.5 h), days 7, 8, 14, 15;
Slovenian: (0,5 ure), 7., 8., 14., 15. dan;
English: In clinical trials, there was an increased incidence of these events in the elderly and those with a prior history of cardiac disease.
Slovenian: V kliničnih preskušanjih so bili ti učinki pogostejši pri starejših in pri bolnikih z anamnezo bolezni srca.
English: Study 0102 38-month data Myeloid blast crisis (n=260)
Slovenian: Študija 0102 podatki pri 38 mesecih mieloidna blastna kriza (n = 260)
English: Table 5 Chemotherapy regimen used in combination with imatinib in study I2301
Slovenian: Preglednica 5 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom v študiji I2301
English: • Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
Slovenian: • odraslih in pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi;
English: FIP1L1-PDGFRα-positive in other 3 published reports.
Slovenian: FIP1L1-PDGFRα pozitivni so bili še štirje bolniki s HES, ki so jih opisovali v drugih 3 objavljenih poročilih.
English: C/C, n. 4, Poligono Industrial Malpica, 50016 Zaragoza Spain
Slovenian: C/C, n. 4, Poligono Industrial Malpica, 50016 Zaragoza Španija
English: Danmark Teva Denmark A/S Tlf: +45 44985511
Slovenian: Teva Denmark A/S Tlf: +45 44985511
English: Major cytogenetic response, haematological response, molecular response (evaluation of minimal residual disease), time to accelerated phase or blast crisis and survival are main secondary endpoints.
Slovenian: Pomemben citogenetični odziv, hematološki odziv, molekularni odziv (ovrednotenje minimalne rezidualne bolezni), čas do pospešene faze ali blastne krize in preživetje so poglavitni sekundarni cilji opazovanja.
English: 20 out of the 50 (40%) patients in cohort 5 received haematopoietic stem cell transplant.
Slovenian: od 50 bolnikom (40 %) v 5. kohorti so presadili krvotvorne matične celice.
English: The length of the capsule is from 19.1 mm to 19.7 mm and the width is 6.91 mm. Imatinib Teva 400 mg hard capsules
Slovenian: Dolžina kapsule znaša od 19,1 mm do 19,7 mm in je široka 6,91 mm. Imatinib Teva 400 mg trde kapsule
English: • The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Slovenian: • zdravljenje odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
English: In the event of overdose the patient should be observed and appropriate symptomatic treatment given.
Slovenian: V primeru prevelikega odmerjanja je treba bolnika opazovati in mu nuditi ustrezno simptomatsko zdravljenje.
English: A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1-35%)
Slovenian: Pomemben odziv združuje tako popolne kot delne odzive: popoln (0 % Ph+ metafaz), delen (1
English: (1 h), days 26, 46;
Slovenian: (1 ura), 26., 46. dan;
English: For the patients treated at 600 mg, the current estimates for median progression-free-survival and overall survival were 22.9 and 42.5 months, respectively.
Slovenian: Za bolnike, zdravljene s 600 mg, je trenutna ocena medianega preživetja brez napredovanja bolezni in preživetja nasploh 22,9 oziroma 42,5 meseca.
English: The effect of imatinib treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported imatinib data with the primary data from another Phase III study using IFN+Ara-C (n=325) in an identical regimen.
Slovenian: Vpliv zdravljenja z imatinibom na preživetje v kronični fazi pri novo diagnosticirani KML so nadalje preiskovali z retrospektivno analizo zgoraj opisanih podatkov o imatinibu skupaj s prvotnimi podatki druge študije faze III, v kateri so uporabljali IFN+Ara-C s povsem enakim režimom zdravljenja (n = 325).
English: If you forget to take Imatinib Teva - If you forget a dose, take it as soon as you remember.
Slovenian: Če ste pozabili vzeti zdravilo Imatinib Teva - Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
English: When needed, discontinuation of Imatinib Teva treatment may be considered.
Slovenian: Če je treba, velja razmisliti o prekinitvi zdravljenja z zdravilom Imatinib Teva.
English: Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v.
Slovenian: Ara-C: citozin arabinozid; CP: ciklofosfamid; DEX: deksametazon; MTX: metotreksat; 6-MP: 6merkaptopurin; VM26: tenipozid; VCR: vinkristin; IDA: idarubicin; i.v.
English: In this retrospective analysis, the superiority of imatinib over IFN+Ara-C in overall survival was demonstrated (p<0.001); within 42 months, 47 (8.5%) imatinib patients and 63 (19.4%) IFN+Ara-C patients had died.
Slovenian: V tej retrospektivni analizi se je z vidika celotnega preživetja imatinib izkazalo za boljše od IFN+Ara-C (p < 0,001): v 42 mesecih je umrlo 47 (8,5 %) bolnikov z imatinibom in 63 (19,4 %) bolnikov z IFN+Ara-C.
English: Accelerated phase
Slovenian: Predhodna faza
English: When and how to take Imatinib Teva - Take Imatinib Teva with a meal.
Slovenian: Kdaj in kako jemati zdravilo Imatinib Teva Zdravilo Imatinib Teva vzemite z obrokom hrane.
English: Complete (Confirmed3) [95% CI]
Slovenian: popoln (potrjen3) [95 %-ni interval zaupanja] delen
English: For adult patients with relapsed or refractory Ph+ALL imatinib monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs.
Slovenian: Za odrasle bolnike z relapsom ali neodzivno Ph+ ALL je imatinib kot monoterapija v odmerku 600 mg/dan varen in učinkovit ter ga lahko prejemajo dokler ne pride do napredovanja bolezni.
English: Major molecular response criteria: in the peripheral blood reduction of ≥ 3 logarithms in the amount of Bcr-Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline.
Slovenian: Kriteriji pomembnega molekularnega odziva: zmanjšanje količine Bcr-Abl transkriptov v periferni krvi za ≥ 3 logaritme (merjeno s kvantitativno PCR določitvijo reverzne transkriptaze v realnem času) glede na standardizirane izhodiščne vrednosti.
English: Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients.
Slovenian: Pri tem je pomembno, da je 27,7 % bolnikov doseglo tudi pomemben citogenetični odziv, ki je bil pri 20,4 %
English: One large, open-label, multicentre, international randomised phase III study has been conducted in patients with newly diagnosed Ph+ CML.
Slovenian: Eno veliko odprto, multicentrično, mednarodno randomizirano študijo tretje faze so opravili pri bolnikih z na novo diagnosticirano Ph+ KML.
English: - Women who might become pregnant are advised to use effective contraception during treatment.
Slovenian: Ženskam, ki bi lahko zanosile, med zdravljenjem priporočamo uporabo učinkovite kontracepcijske metode.
English: For patients with reduction in Bcr-Abl transcripts of at least 3 logarithms at 12 months, the probability of remaining free from progression to accelerated phase/blast crisis was 99% at 84 months.
Slovenian: Pri bolnikih z zmanjšanjem števila transkriptov Bcr-Abl za vsaj 3 logaritme pri 12 mesecih je bila verjetnost, da bolezen ne napreduje v pospešeno fazo/blastno krizo, po 84 mesecih 99 %.
English: Of these 11 patients, 4 patients escalated up to 800 mg daily, 2 of whom regained a cytogenetic response (1 partial and 1 complete, the latter also achieving a molecular response), while of the 7 patients who did not escalate the dose, only one regained a complete cytogenetic response.
Slovenian: Od teh 11 bolnikov so 4 bolnikom zvečali odmerek na 800 mg na dan, od njih sta 2 spet dobila citogenetični odziv (1 delnega in 1 popolnega, le-ta je dosegel tudi molekularni odziv), medtem ko je od 7 bolnikov, pri katerih odmerka niso zvečali, le eden spet dobil popolni citogenetični odziv.
English: Imatinib Teva inhibits the growth of these cells.
Slovenian: Zdravilo Imatinib Teva zavira rast teh celic.
English: The median duration of therapy in the published literature ranged between 4 weeks and more than 20 months.
Slovenian: Mediano trajanje zdravljenja v objavljeni literaturi se je gibalo od 4 tednov do več kot
English: Check whether cytopenia is related to leukaemia (marrow aspirate or biopsy).
Slovenian: 1.Preverite, ali je citopenija povezana z levkemijo (aspirat ali biopsija kostnega mozga).
English: If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Teva should not be resumed.
Slovenian: primeru, da je koncentracija protiteles proti ADAMTS13 zvišana, aktivnost ADAMTS13 pa nizka, se zdravljenja z zdravilom Imatinib Teva ne sme nadaljevati.
English: However, since the effects of low-dose exposure of the infant to imatinib are unknown, women taking imatinib should not breastfeed.
Slovenian: Vendar učinki izpostavljenosti dojenčka majhnim odmerkom imatiniba niso znani, zato ženske, ki jemljejo imatinib ne smejo dojiti.
English: days 1-3;
Slovenian: 1.-3. dan;
English: Not applicable Not applicable
Slovenian: se smiselno ne uporablja se smiselno ne uporablja
English: Lymphoid blast crisis
Slovenian: Limfoidna blastna kriza
English: The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Slovenian: Izkušnje z uporabo imatiniba pri bolnikih z MDS/MPD v povezavi s preureditvijo genov za PDGFR so zelo omejene (glejte poglavje 5.1).
English: The active substance imatinib demonstrates an environmental risk for sediment organisms.
Slovenian: Zdravilna učinkovina imatinib predstavlja okoljsko tveganje za organizme v sedimentih.
English: Imatinib inhibits signalling and proliferation of cells driven by dysregulated PDGFR and Abl kinase activity.
Slovenian: Imatinib zavira signaliziranje in proliferacijo celic, ki ju povzroča napačno uravnavano delovanje PDGFR in aktivnosti Abl kinaze.
English: Remission induction
Slovenian: Indukcija remisije
English: Haematological response1 Complete haematological response (CHR) No evidence of leukaemia (NEL)
Slovenian: Hematološki odziv1 popolni hematološki odziv (CHR) nobenih znakov levkemije (NEL)
English: The first 77 patients were started at 400 mg, the protocol was subsequently amended to allow higher dosing and the remaining 158 patients were started at 600 mg.
Slovenian: Prvih 77 bolnikov je začelo zdravljenje z odmerkom 400 mg, pozneje je bil protokol dopolnjen, da je omogočil večje odmerjanje in je preostalih 158 bolnikov začelo s 600 mg.
English: Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys.
Slovenian: Hepatotoksičnost Presnova imatiniba poteka predvsem v jetrih in le 13 % se izloča skozi ledvice.
English: • Eye pain or deterioration in vision, bleeding in the eyes.
Slovenian: • bolečine v očeh ali poslabšanje vida, očesna krvavitev,
English: • Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Slovenian: • odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) in/ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFRα.
English: Imatinib Teva may do the same to some other medicines.
Slovenian: Zdravilo Imatinib Teva lahko enako vpliva na nekatera druga zdravila.
English: Do not stop taking Imatinib Teva unless your doctor tells you to.
Slovenian: Ne prenehajte jemati zdravila Imatinib Teva, razen če vam tako naroči zdravnik.
English: A total of 71 (12.8%) and 85 (15.4%) patients died in the imatinib and IFN+Ara-C groups, respectively.
Slovenian: Skupno je umrlo 71 (12,8 %) bolnikov iz skupine z imatinibom in 85 (15,4 %) iz skupine z IFN+AraC.
English: Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG, Belgique/Belgien
Slovenian: Teva Pharma Belgium N.V./S.A./AG, Belgique/Belgien
English: Therapy should be initiated by a physician experienced in the treatment of patients with haematological malignancies and malignant sarcomas, as appropriate.
Slovenian: 4.2 Odmerjanje in način uporabe Zdravljenje mora začeti zdravnik, izkušen v zdravljenju bolnikov s hematološkimi malignimi boleznimi in malignimi sarkomi, kot je primerno.
English: Other medicines and Imatinib Teva
Slovenian: Druga zdravila in zdravilo Imatinib Teva
English: In the juvenile toxicology study, effects upon growth, delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2 times the average paediatric exposure at the highest recommended dose of 340 mg/m2.
Slovenian: V študiji toksičnih učinkov na razvoj mladičev so opažali vpliv na rast ter zakasnjeno odpiranje nožnice in ločevanje prepucija pri izpostavljenosti, ki ustreza približno 0,3 do 2-kratniku izpostavljenosti, do kakršne v povprečju pride pri otrocih, ki prejemajo največji priporočeni odmerek 340 mg/m2.
English: Imatinib Teva is a medicine containing an active substance called imatinib.
Slovenian: Zdravilo Imatinib Teva je zdravilo, ki vsebuje zdravilno učinkovino z imenom imatinib.
English: Imatinib at 400 mg twice daily had an inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23% (90%CI [1.16-1.30]).
Slovenian: Imatinib je v odmerku 400 mg dvakrat na dan zaviral presnovo metoprolola s CYP2D6, tako da sta se Cmax in AUC metoprolola povečali za približno 23 % (90 % IZ [1,16-1,30]).
English: Depression, libido decreased, anxiety
Slovenian: depresija, zmanjšan libido, anksioznost redki:
English: The more frequent adverse reactions included gastrointestinal haemorrhages, conjunctivitis and elevation of transaminases or bilirubin.
Slovenian: Med pogostejšimi neželenimi reakcijami so bili gastrointestinalne krvavitve, konjunktivitis in zvišanje aminotransferaz ali bilirubina.
English: These patients received imatinib for a median of 47 months (range 24 days - 60 months).
Slovenian: Ti bolniki so prejemali imatinib mediano 47 mesecev (od 24 dni do 60 mesecev).
English: In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in these patients.
Slovenian: Kaže, da je pri bolnikih z okvarjenim delovanjem ledvic izpostavljenost imatinibu v plazmi višja kot pri bolnikih z normalnim delovanjem ledvic, verjetno zato, ker je pri teh bolnikih zvišana vrednost alfa kislega glikoproteina (AGP - alpha-acid glycoprotein) v plazmi, proteina, ki veže imatinib.
English: These are blood diseases in which some blood cells (named eosinophils) start growing out of control.
Slovenian: To so bolezni krvi, pri katerih se začnejo nenadzorovano razraščati nekatere krvne celice (imenovane eozinofilci).
English: Imatinib Teva can help you to fight this condition.
Slovenian: Zdravilo Imatinib Teva vam lahko pomaga pri premagovanju te bolezni.
English: Posology for Ph+ ALL in paediatric patients Dosing for children should be on the basis of body surface area (mg/m2).
Slovenian: Odmerjanje pri Ph+ ALL pri pediatričnih bolnikih Odmerjanje za otroke mora temeljiti na telesni površini (mg/m2).
English: If a severe non-haematological adverse reaction develops with imatinib use, treatment must be withheld until the event has resolved.
Slovenian: Če med uporabo imatiniba nastopi huda nehematološka neželena reakcija, je treba Zdravljenje prekiniti, dokler reakcija ne izzveni.
English: In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with DFSP.
Slovenian: Pri odraslih in pediatričnih bolnikih temelji učinkovitost imatiniba na celotni hematološki in citogenetični odzivnosti in preživetju brez napredovanja bolezni pri KML, na hematološki in citogenetični odzivnosti pri Ph+ ALL, MDS/MPD, na hematološki odzivnosti pri HES/CEL ter na objektivni odzivnosti odraslih bolnikov z DFSP.
English: Treatment schedule: On the basis of the existing data, imatinib has been shown to be effective and safe when administered at 600 mg/day in combination with chemotherapy in the induction phase, the consolidation and maintenance phases of chemotherapy (see section 5.1) for adult patients with newly diagnosed Ph+ ALL.
Slovenian: Razpored zdravljenja: Na osnovi obstoječih podatkov se je imatinib izkazal kot učinkovit in varen, če je bil pri odraslih bolnikih z novo diagnosticirano Ph+ALL uporabljen v odmerku 600 mg/dan v kombinaciji s kemoterapijo v začetni fazi, konsolidacijski in vzdrževalni fazi kemoterapije (glejte poglavje 5.1).
English: Imatinib Teva may cause your body to retain water (severe fluid retention).
Slovenian: Zaradi zdravila Imatinib Teva lahko telo zadržuje vodo (lahko pride do hudega zastajanja tekočine).
English: The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations.
Slovenian: Način uporabe Predpisani odmerek mora bolnik vzeti peroralno z obrokom in velikim kozarcem vode, da se čim bolj zmanjša tveganje draženja prebavil.
English: Deutschland AbZ-Pharma GmbH Tel: +49 73140205
Slovenian: AbZ-Pharma GmbH Tel: +49 73140205
English: When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females.
Slovenian: dni pred parjenjem in nato ves čas do 6. dne brejosti, ni bilo nikakršnega učinka na parjenje ali na število brejih samic.
English: Study ADE04 Prephase
Slovenian: Študija ADE04
English: How long to take Imatinib Teva Keep taking Imatinib Teva every day for as long as your doctor tells you.
Slovenian: Koliko časa jemati zdravilo Imatinib Teva Zdravilo Imatinib Teva jemljite vsak dan, dokler vam zdravnik ne naroči, da ga prenehate jemati.
English: If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 260 mg/m2.
Slovenian: Če citopenija ni povezana z levkemijo, zmanjšajte odmerek imatiniba na 260 mg/m2.
English: Imatinib in combination with chemotherapy induction (see Table 4) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients).
Slovenian: Imatinib je v kombinaciji z indukcijo s kemoterapijo (glejte preglednico 3) povzročil popolni hematološki odziv pri 93 % (147 od 158 za oceno primernih bolnikov) in pomembni citogenetični odziv pri 90 % (19 od 21 za oceno primernih bolnikov).
English: Alternating chemotherapy course: high dose chemotherapy with MTX 1 g/m2 i.v.
Slovenian: Konsolidacijsko zdravljenje izmenična kemoterapija: visokoodmerna kemoterapija z MTX 1 g/m i.v.
English: Maximal plasma concentrations of imatinib in patients are 2-4 µmol/l, consequently an inhibition of CYP2D6 and/or CYP3A4/5-mediated metabolism of co-administered drugs is possible.
Slovenian: Največje koncentracije imatiniba v plazmi bolnikov so 2-4 μmol/l, zato je možna inhibicija sočasno uporabljanih zdravil s presnovo, ki poteka preko CYP2D6 in/ali CYP3A4/5.
English: With 7 years follow-up, there were 93 (16.8%) progression events in the imatinib arm: 37 (6.7%) involving progression to accelerated phase/blast crisis, 31 (5.6%) loss of MCyR, 15 (2.7%) loss of CHR or increase in WBC, and 10 (1.8%) CML unrelated deaths.
Slovenian: Po 7 letih spremljanja je bilo v kraku z imatinibom 93 (16,8 %) dogodkov, ki pomenijo napredovanje bolezni: 37 (6,7 %) jih je vključevalo napredovanje v pospešeno fazo/blastno krizo, 31 (5,6 %) izgubo pomembnega citogenetičnega odziva, 15 (2,7 %) izgubo popolnega hematološkega odziva ali zvišanje WBC, 10 (1,8 %) pa je bilo smrti brez povezave s KML.